KYMR — Kymera Therapeutics, Inc.
Is KYMR overbought or oversold? Here is the current MarketMoodz read.
Kymera Therapeutics, Inc. (KYMR) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $107.39. The rating moved from Oversold to Strong Oversold on October 2, 2026.
- Public ratingStrong Oversold (as of October 3, 2026)
- Last close$107.39
- Last changeMoved from Oversold to Strong Oversold on October 2, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Kymera has a differentiated targeted protein degradation platform and collaborations that underpin medium‑to‑long‑term upside if clinical programs deliver positive data or partnerships broaden. Near term the company faces typical biotech risks: binary clinical catalysts, cash runway sensitivity and dilution risk. Macro headwinds — recent risk‑off sentiment, a cooling healthcare IPO window and intensifying payer focus on drug pricing — increase volatility and reduce conviction for a strong directional move absent favorable readouts or clear partnership news. The most plausible positive scenarios are successful clinical readouts or strategic financing/partnership announcements that restore investor confidence; downside scenarios are negative trial results, funding difficulties, or adverse policy/payer developments that materially compress valuations.
Key factors
- Proprietary targeted protein degradation platform with multiple pipeline candidates supporting long‑term value creation if clinical proofs succeed
- Partnerships and collaboration optionality that can provide non‑dilutive funding, validation and upside through milestone/licensing payments
- Clinical catalysts on the horizon (readouts/dose-escalation updates) that could re-rate the stock if positive
- Macroeconomic and sector environment: recent risk‑off tone and healthcare IPO cooling are suppressing near‑term appetite for biotech risk
- Policy/payer environment (Medicare drug‑price negotiation) increasing long‑term pricing uncertainty for novel therapeutics
- Valuation sensitivity and limited near‑term revenue; equity moves will be driven largely by binary clinical/regulatory news
Risks
- Clinical trial failures, delays or negative readouts that could sharply reduce valuation for early/mid‑stage assets
- Material cash burn and the need to raise capital at potentially unfavorable valuations, leading to dilution
- Adverse regulatory decisions or slow regulatory timelines for novel modalities like targeted protein degradation
- Downward pricing pressure and access risk from Medicare negotiation and payer scrutiny for high‑cost specialty therapies
- Dependence on partnerships; termination or unfavorable renegotiation of collaborations could remove expected funding or validation
- Broader market risk‑off episodes that compress biotech multiples and reduce M&A or financing optionality
- Manufacturing, CMC or scale‑up challenges for complex biologic/degrader modalities
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for KYMR — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.